NCT06606821 (IDEAL-COR) is a Phase 4 clinical trial of Tirzepatide in Coronary Artery Disease, sponsored by Tina Vilsbøll.

Who is sponsoring NCT06606821?

NCT06606821 is sponsored by Tina Vilsbøll.

What drugs are being tested in NCT06606821?

Interventions in NCT06606821: Tirzepatide, Placebo.

What condition does NCT06606821 study?

NCT06606821 studies Coronary Artery Disease, Coronary Microvascular Dysfunction, Overweight or Obesity, Stable Angina Pectoris, Chronic Coronary Artery Disease, Atherosclerosis Cardiovascular Disease.

Is NCT06606821 still recruiting?

NCT06606821 is currently recruiting now. Last updated 22 May 2025.

Last reviewed 2025-05-22 · How we verify

NCT06606821: IDEAL-COR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

Recruiting now Phase 4 Last updated 22 May 2025

What this trial tests

Phase 4 trial testing Tirzepatide in Coronary Artery Disease in 124 participants. Currently enrolling.

Timeline

1 October 2024

Primary endpoint
20 March 2027

1 August 2028

Quick facts

Lead sponsor	Tina Vilsbøll
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	124
Start date	1 October 2024
Primary completion	20 March 2027
Estimated completion	1 August 2028
Sites	3 locations across Denmark

Drugs / interventions tested

Tirzepatide (TIRZEPATIDE) — full drug profile →
Placebo

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Coronary Microvascular Dysfunction — all drugs for Coronary Microvascular Dysfunction →
Overweight or Obesity — all drugs for Overweight or Obesity →
Stable Angina Pectoris — all drugs for Stable Angina Pectoris →

Sponsor

Tina Vilsbøll

Who can join

18 and older, any sex, with Coronary Artery Disease or Coronary Microvascular Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to investigate, as a proof-of-principle, long-term (52 weeks) effects of tirzepatide once-weekly vs. placebo on changes in coronary plaque composition and progression (assessed by NIRS), plaque burden (assessed by IVUS) and microvascular function (assessed by invasively measured CFR) in overweight and obese individuals with stable coronary artery disease (CAD). In addition, the objective of a baseline cross-sectional sub-study is to explore potential metabolic and cardiovascular (CV) predictors for high arteriosclerotic plaque burden in overweight and obese individuals and to establish a cohort for future research projects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Epicardial adipose tissue in coronary microvascular disease.
Gašpárková V, Tran BT, Ošťádal P, Lambert L, et al · · 2026 · PMID 41694543 · DOI 10.1016/j.ahjo.2026.100734

Verify or expand the search:

Other trials of Tirzepatide

Trials testing the same drug.

NCT07468552 — Trial of Tirzepatide for the Treatment of Cannabis Use Disorder · Phase 2 · not yet recruiting
NCT06732245 — Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese · Phase 2 · not yet recruiting
NCT07349641 — A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia · Phase 2 · not yet recruiting
NCT07265752 — Tirzepatide for the Treatment of Cannabis Use Disorder · Phase 2 · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06606821 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tina Vilsbøll
Last refreshed: 22 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06606821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing